Date | Time | Source | Headline | Symbol | Company |
10/30/2006 | 11:34AM | Business Wire | Covalent Group Changes Name to Encorium Group, Inc. | NASDAQ:CVGR | Covalent |
10/20/2006 | 4:08PM | Business Wire | Covalent Group, Inc. Announces Results of Shareholder Vote | NASDAQ:CVGR | Covalent |
10/19/2006 | 8:01AM | Business Wire | Covalent Signs $8.2 Million in Contracts For Multinational Studies to Treat Influenza | NASDAQ:CVGR | Covalent |
08/08/2006 | 4:36PM | Business Wire | Covalent Reports 2006 Second Quarter Financial Results; Company to Hold Conference Call at 9:00 AM on Wednesday, August 9, 2006 | NASDAQ:CVGR | Covalent |
08/07/2006 | 8:24AM | Business Wire | Covalent Group, Inc. Announces $1.7 Million Contract For Phase 2 Clinical Trial in Atherosclerosis | NASDAQ:CVGR | Covalent |
08/02/2006 | 10:14AM | Business Wire | Covalent Group, Inc. Schedules Second Quarter Financial Results and Conference Call | NASDAQ:CVGR | Covalent |
07/13/2006 | 12:00PM | Business Wire | Covalent Group, Inc. Signs Contracts Totaling $1.5 Million for Clinical Studies Offering Advanced Therapeutic Approaches to Pat | NASDAQ:CVGR | Covalent |
07/06/2006 | 2:15PM | Business Wire | Covalent Group Amends Business Combination Agreement with Remedium Oy | NASDAQ:CVGR | Covalent |
06/28/2006 | 8:27AM | Business Wire | Covalent Group, Inc. Announces $2.1 Million of New Business Contracts; Reiterates Second Quarter Guidance | NASDAQ:CVGR | Covalent |
05/15/2006 | 5:22PM | Business Wire | Covalent Reports 2006 First Quarter Financial Results and Summary Balance Sheet Data; Company to Hold Conference Call at 9:00 A | NASDAQ:CVGR | Covalent |
05/08/2006 | 8:12AM | Business Wire | Covalent Group, Inc. Schedules First Quarter Financial Results and Conference Call | NASDAQ:CVGR | Covalent |
04/20/2006 | 8:07AM | Business Wire | Covalent Group, Inc. Signs $1 Million Contract To Conduct Phase 1 Study of Drug to Prevent/Treat Infectious Disease | NASDAQ:CVGR | Covalent |
03/30/2006 | 8:00AM | Business Wire | Covalent Group, Inc. Announces Additional New Business Contracts | NASDAQ:CVGR | Covalent |
03/21/2006 | 5:15PM | Business Wire | Covalent Group, Inc. Announces $2.1 Million Contract To Conduct Patient Disease Registry In Hospitalized Subjects With Hyponatr | NASDAQ:CVGR | Covalent |
03/21/2006 | 5:14PM | Business Wire | Covalent Group, Inc. Signs $1.3 Million in Consulting and Medical Writing Contracts to Support New Drug Applications (NDA) for | NASDAQ:CVGR | Covalent |
03/21/2006 | 5:12PM | Business Wire | Covalent Reports 2005 Fourth Quarter and Year End Financial Results and Summary Balance Sheet Data; Company to Hold Conference | NASDAQ:CVGR | Covalent |
03/16/2006 | 7:57AM | Business Wire | Covalent Group, Inc. Schedules Fourth Quarter Financial Results and Conference Call | NASDAQ:CVGR | Covalent |
03/03/2006 | 8:12AM | Business Wire | Covalent Group, Inc. Enters into Combination Agreement with Remedium Oy; Conference Call Scheduled for 11:00 AM ET Today | NASDAQ:CVGR | Covalent |
02/08/2006 | 9:31AM | Business Wire | Covalent Group, Inc. and Sudler & Hennessey Announce Strategic Partnership to Design and Conduct Global Patient Disease Registri | NASDAQ:CVGR | Covalent |
02/02/2006 | 8:01AM | Business Wire | Covalent Group, Inc. Signs $2.2 Million Contract With New Sponsor to Conduct Clinical Trial in Patients with Cardiovascular Dise | NASDAQ:CVGR | Covalent |
01/31/2006 | 12:00PM | Business Wire | Covalent Group, Inc. Retains The Equity Group to Provide Investor Relations Services | NASDAQ:CVGR | Covalent |
01/24/2006 | 8:00AM | PR Newswire (US) | Covalent Group, Inc. Announces Multiple New Business Contracts with an Aggregate Value of $1.0 Million | NASDAQ:CVGR | Covalent |
01/18/2006 | 8:00AM | PR Newswire (US) | Covalent Group, Inc. Signs Contract for $2.3 Million to Conduct a Multinational Phase 2 Clinical Trial Involving a New Antithrom | NASDAQ:CVGR | Covalent |
12/08/2005 | 7:00AM | PR Newswire (US) | Covalent Group, Inc. Signs Letter-of-Intent to Conduct $2.2 Million Multinational Phase 2 Clinical Trial in Cardiovascular Disea | NASDAQ:CVGR | Covalent |
12/05/2005 | 7:01AM | PR Newswire (US) | Covalent Group, Inc. and Emergent BioSolutions Sign Contract to Develop Immune Globulins for Treatment Exposure of Anthrax Infec | NASDAQ:CVGR | Covalent |
11/18/2005 | 9:30AM | PR Newswire (US) | CSC's DVC Reaches Milestone in Plague Vaccine Clinical Trial | NASDAQ:CVGR | Covalent |
11/11/2005 | 10:20AM | PR Newswire (US) | /C O R R E C T I O N -- Covalent Group, Inc. / | NASDAQ:CVGR | Covalent |
11/10/2005 | 5:01PM | PR Newswire (US) | Covalent Reports Results for Third Quarter 2005 | NASDAQ:CVGR | Covalent |
11/07/2005 | 8:03AM | PR Newswire (US) | Covalent Group, Inc. to Report Third Quarter 2005 Results on Thursday, November 10 | NASDAQ:CVGR | Covalent |
10/06/2005 | 9:01AM | PR Newswire (US) | Covalent Group, Inc. Announces $5.3 Million Contract to Provide Additional Services for a Global Phase 3 Trial in Hypertension | NASDAQ:CVGR | Covalent |